No Data
No Data
12 Health Care Stocks Moving In Friday's Intraday Session
MediciNova (NASDAQ:MNOV) Shareholders Have Endured a 73% Loss From Investing in the Stock Five Years Ago
MediciNova Announces That The National Institutes Of Health Neurological Disorders And Stroke Has Awarded $22M For An Intermediate Size Expanded Access Protocol To Evaluate The Efficacy Of MN-166 In Amyotrophic Lateral Sclerosis
Express News | MediciNova Inc - Nih Awards $22 Million for Eap to Evaluate Mn-166 in ALS
Express News | Medicinova to Support Nih-Funded Expanded Access Clinical Trial to Evaluate Mn166 (Ibudilast) in Amyotrophic Lateral Sclerosis (ALS)
Medicinova and others continue to rank in, with clinical trials starting for ALS (amyotrophic lateral sclerosis) treatments.
Medicinova <4875> has ranked in (as of 10:32). It is significantly up. On the 23rd yesterday, it was announced that the company has received new Expand Access Program research grants from the National Institutes of Health (NIH) in the USA, and has initiated clinical trials targeting ALS patients with MN-166 (Ibudilast) being developed, being considered a buying catalyst. Details are being coordinated with relevant agencies.
No Data
No Data